StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mylan (MYL) and Aspen Report Launch of Generic Busulfex Injection
December 4, 2017 7:36 AM
Mylan N.V. (NASDAQ: MYL) and its partner, Aspen, today announced the U.S. launch of Myleran (busulfan) Injection, 60 mg/10 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Mylan and Aspen Announce Launch of Generic Busulfex® Injection
December 4, 2017 7:30 AM
Tech firms tell patent court to ignore Allergan deal with tribe
December 1, 2017 5:59 PM
Mylan (MYL) and Biocon Announce FDA Approval for Ogivri to Treat HER2-Positive Breast and Gastric Cancers
December 1, 2017 11:33 AM
Mylan (MYL) Reports FDA Approval of Heparin Sodium Injection
December 1, 2017 10:53 AM
Mylan's (MYL) Biosimilar to Roche's Herceptin Wins FDA Approval
December 1, 2017 10:46 AM
Mylan (MYL) Spikes Post-Market After CNBC says Amazon Exploring Talks with Generic Drugmakers
November 30, 2017 5:08 PM
Amazon (AMZN) Exploring Talks with Generic-Drug Makers - CNBC
November 30, 2017 5:02 PM
Cantor Fitzgerald Sees ~4.9M Shares of Teva (TEVA) Being Bought Amid TASE Index Rebalance
November 30, 2017 12:22 PM
